ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $587,854 | +761.2% | 14,303 | +878.3% | 0.01% | +400.0% |
Q1 2024 | $68,261 | +3.6% | 1,462 | +6.1% | 0.00% | +100.0% |
Q4 2023 | $65,896 | -48.3% | 1,378 | -61.4% | 0.00% | -75.0% |
Q3 2023 | $127,378 | -83.5% | 3,573 | -78.7% | 0.00% | -84.6% |
Q2 2023 | $773,554 | +585925.8% | 16,769 | +408.6% | 0.03% | +550.0% |
Q1 2023 | $132 | -71.2% | 3,297 | -66.7% | 0.00% | -78.9% |
Q4 2022 | $459 | -99.8% | 9,911 | +41.5% | 0.02% | +280.0% |
Q3 2022 | $290,000 | -8.5% | 7,005 | +32.1% | 0.01% | -28.6% |
Q2 2022 | $317,000 | +21.9% | 5,302 | +48.6% | 0.01% | +250.0% |
Q1 2022 | $260,000 | +20.4% | 3,569 | +38.6% | 0.00% | -50.0% |
Q4 2021 | $216,000 | -31.9% | 2,575 | -26.9% | 0.00% | -50.0% |
Q3 2021 | $317,000 | -72.7% | 3,521 | -71.1% | 0.01% | -73.3% |
Q2 2021 | $1,162,000 | +133.8% | 12,190 | +179.6% | 0.03% | +275.0% |
Q1 2021 | $497,000 | +13.7% | 4,360 | +38.0% | 0.01% | -38.5% |
Q4 2020 | $437,000 | +5.6% | 3,159 | -37.3% | 0.01% | +160.0% |
Q3 2020 | $414,000 | -23.8% | 5,040 | -27.4% | 0.01% | -77.3% |
Q2 2020 | $543,000 | +1710.0% | 6,940 | +883.0% | 0.02% | +1000.0% |
Q4 2019 | $30,000 | +2900.0% | 706 | +1976.5% | 0.00% | – |
Q3 2019 | $1,000 | -85.7% | 34 | -69.1% | 0.00% | – |
Q2 2019 | $7,000 | -86.0% | 110 | -83.2% | 0.00% | -100.0% |
Q3 2018 | $50,000 | +6.4% | 655 | -35.2% | 0.00% | -33.3% |
Q4 2017 | $47,000 | -66.2% | 1,011 | -61.3% | 0.01% | -45.5% |
Q3 2017 | $139,000 | – | 2,611 | +52120.0% | 0.01% | – |
Q2 2017 | $0 | -100.0% | 5 | -98.9% | 0.00% | -100.0% |
Q4 2016 | $33,000 | +175.0% | 465 | +181.8% | 0.00% | +300.0% |
Q3 2016 | $12,000 | -7.7% | 165 | -38.7% | 0.00% | 0.0% |
Q2 2016 | $13,000 | -63.9% | 269 | -53.1% | 0.00% | -80.0% |
Q1 2016 | $36,000 | -34.5% | 573 | +17.9% | 0.01% | -44.4% |
Q4 2015 | $55,000 | +1000.0% | 486 | +872.0% | 0.01% | – |
Q2 2015 | $5,000 | -28.6% | 50 | -53.7% | 0.00% | -100.0% |
Q1 2015 | $7,000 | +250.0% | 108 | +300.0% | 0.00% | – |
Q3 2014 | $2,000 | -86.7% | 27 | -91.4% | 0.00% | -100.0% |
Q1 2014 | $15,000 | – | 314 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
First Light Asset Management, LLC | 217,459 | $24,760,000 | 1.64% |
Motley Fool Asset Management LLC | 152,326 | $17,344,000 | 1.25% |
Rock Springs Capital Management LP | 450,000 | $51,237,000 | 1.12% |
AtonRa Partners | 21,017 | $2,393,000 | 1.07% |
SECTORAL ASSET MANAGEMENT INC | 112,200 | $12,775,000 | 0.97% |
EMERALD ADVISERS, LLC | 228,368 | $26,002,000 | 0.94% |
EMERALD MUTUAL FUND ADVISERS TRUST | 239,023 | $27,215,000 | 0.90% |
FEDERATED HERMES, INC. | 3,912,408 | $445,467,000 | 0.86% |
HealthCor Management, L.P. | 207,610 | $23,638,000 | 0.84% |
Atika Capital Management LLC | 66,000 | $7,515,000 | 0.65% |